APA

Okimoto R. A., Lin L., Olivas V., Chan E., Markegard E., Rymar A., Neel D., Chen X., Hemmati G., Bollag G. & Bivona T. G. (20180330). Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. : Proceedings of the National Academy of Sciences of the United States of America.

Chicago

Okimoto Ross A, Lin Luping, Olivas Victor, Chan Elton, Markegard Evan, Rymar Andrey, Neel Dana, Chen Xiao, Hemmati Golzar, Bollag Gideon and Bivona Trever G. 20180330. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. : Proceedings of the National Academy of Sciences of the United States of America.

Harvard

Okimoto R. A., Lin L., Olivas V., Chan E., Markegard E., Rymar A., Neel D., Chen X., Hemmati G., Bollag G. and Bivona T. G. (20180330). Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. : Proceedings of the National Academy of Sciences of the United States of America.

MLA

Okimoto Ross A, Lin Luping, Olivas Victor, Chan Elton, Markegard Evan, Rymar Andrey, Neel Dana, Chen Xiao, Hemmati Golzar, Bollag Gideon and Bivona Trever G. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. : Proceedings of the National Academy of Sciences of the United States of America. 20180330.